Genetic Technologies Limited (NASDAQ:GENE)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.92 and traded as high as $1.96. Genetic Technologies shares last traded at $1.96, with a volume of 200 shares.

Separately, ValuEngine upgraded shares of Genetic Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, September 4th.

The company has a 50-day moving average of $1.36 and a 200 day moving average of $0.92.

A hedge fund recently bought a new stake in Genetic Technologies stock. Alpine Group USVI LLC bought a new stake in shares of Genetic Technologies Limited (NASDAQ:GENE) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 28,437 shares of the biotechnology company’s stock, valued at approximately $25,000. Genetic Technologies comprises about 0.1% of Alpine Group USVI LLC’s holdings, making the stock its 15th biggest position. Alpine Group USVI LLC owned 0.18% of Genetic Technologies at the end of the most recent reporting period. 13.51% of the stock is currently owned by institutional investors and hedge funds.

About Genetic Technologies (NASDAQ:GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

Featured Story: How to interpret the current ratio

Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.